7Vonder Mark K,Kirsch T,Nerlich A,et al.Type X collagen synthesis in human os-teoarthritic cartilage.Indication of chondrocyte hypertrophy.Arthritis Rheum,1992,35:806 ～ 811.
3Silverman RP, Passaretti D, Huang W, et al. Injectable tissueengineered cartilage using a fibrin glue polymer. Plast Reconstr Surg, 1999, 103: 1809-1818.
4Brand DD, Myers LK, Whittington KB, et al. Detection of early changes in autoimmune T cell phenotype and function following intravenous administration of type Ⅱ collagen in a TCR-transgenie model. J Immunol, 2002, 168: 490-498.
5Willians RO, Williams DG, Maini RN. Anti-type Ⅱ collagen ELISA: increased disease specificity following removal of anionic contaminants from salt-fractionated type Ⅱ collagen. J Immunol Methods, 1992, 147: 93-100.
6Nehrer S, Spector M, Minas T. Histologic analysis of tissue after failed cartilage repair procedures. Clin Orthop, 1999, 365: 149-162.
7Myers LK, Rosloniec EF, Cremer MA, et al. Collagen induced arthritis, an animal model of autoimmunity. Life Science, 1997,61: 1861-1878.
8Schneider U, Breusch S J, yon der Mark K. Current status of autologous chondrocyte transplantation. Z Orthop Thre Grenzgeb,1999, 137: 386-392.
9Polgar A, Falus A, Koo E, et al. Elevated levels of synovial fluid antibodies reactive with the small proteoglycans biglycan and decorin in patients with rheumatoid arthritis or other joint diseases. Rheumatology, 2003, 42: 522-527.
10Rousseau JC, Zhu Y, Miossec P, et al. Serum levels of type ⅡAprocollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage, 2004, 12: 440-447.
